 Myron Levin
Concepts (803)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Herpes Zoster | 105 | 2024 | 317 | 18.600 |
Why?
| | Herpes Zoster Vaccine | 65 | 2024 | 162 | 17.010 |
Why?
| | Herpesvirus 3, Human | 86 | 2024 | 331 | 12.600 |
Why?
| | Chickenpox | 24 | 2023 | 80 | 5.200 |
Why?
| | Antibodies, Viral | 66 | 2024 | 602 | 5.180 |
Why?
| | Immunity, Cellular | 36 | 2024 | 265 | 4.730 |
Why?
| | Chickenpox Vaccine | 27 | 2023 | 71 | 3.960 |
Why?
| | Influenza Vaccines | 18 | 2024 | 533 | 2.970 |
Why?
| | Vaccines, Attenuated | 32 | 2024 | 125 | 2.790 |
Why?
| | HIV Infections | 38 | 2018 | 2730 | 2.600 |
Why?
| | Neuralgia, Postherpetic | 18 | 2019 | 40 | 2.490 |
Why?
| | Immunocompromised Host | 13 | 2019 | 199 | 2.450 |
Why?
| | Antiviral Agents | 28 | 2022 | 719 | 2.370 |
Why?
| | Adjuvants, Immunologic | 17 | 2023 | 222 | 2.200 |
Why?
| | Simplexvirus | 24 | 2016 | 80 | 2.150 |
Why?
| | Acyclovir | 27 | 2016 | 99 | 2.080 |
Why?
| | Herpes Simplex | 17 | 2016 | 92 | 1.940 |
Why?
| | Vaccination | 33 | 2023 | 1348 | 1.910 |
Why?
| | DNA, Viral | 24 | 2018 | 347 | 1.780 |
Why?
| | Papillomavirus Vaccines | 13 | 2018 | 232 | 1.670 |
Why?
| | Viral Envelope Proteins | 6 | 2021 | 81 | 1.510 |
Why?
| | Herpesvirus 1, Human | 10 | 2016 | 86 | 1.480 |
Why?
| | Pregnancy Complications, Infectious | 16 | 2020 | 367 | 1.480 |
Why?
| | Influenza, Human | 13 | 2024 | 602 | 1.430 |
Why?
| | Humans | 290 | 2024 | 129847 | 1.420 |
Why?
| | Aged | 92 | 2024 | 22107 | 1.420 |
Why?
| | T-Lymphocytes | 20 | 2019 | 1937 | 1.410 |
Why?
| | Aged, 80 and over | 47 | 2022 | 7066 | 1.380 |
Why?
| | Vaccines, Synthetic | 15 | 2023 | 126 | 1.370 |
Why?
| | Antiretroviral Therapy, Highly Active | 13 | 2017 | 267 | 1.360 |
Why?
| | Immunologic Memory | 12 | 2019 | 349 | 1.330 |
Why?
| | Immunization, Secondary | 13 | 2017 | 87 | 1.290 |
Why?
| | CD4-Positive T-Lymphocytes | 13 | 2023 | 1058 | 1.270 |
Why?
| | Papillomavirus Infections | 9 | 2018 | 297 | 1.240 |
Why?
| | Middle Aged | 100 | 2024 | 31177 | 1.160 |
Why?
| | Female | 154 | 2023 | 68829 | 1.070 |
Why?
| | Double-Blind Method | 32 | 2022 | 1877 | 1.040 |
Why?
| | Male | 138 | 2023 | 63759 | 1.030 |
Why?
| | T-Lymphocyte Subsets | 6 | 2019 | 412 | 0.980 |
Why?
| | Vaccines, Inactivated | 9 | 2023 | 68 | 0.920 |
Why?
| | Chagas Disease | 5 | 2007 | 38 | 0.920 |
Why?
| | Viral Vaccines | 12 | 2014 | 95 | 0.910 |
Why?
| | Incidence | 22 | 2023 | 2646 | 0.900 |
Why?
| | Herpesvirus 2, Human | 6 | 2014 | 28 | 0.870 |
Why?
| | Interferon-gamma | 18 | 2022 | 773 | 0.840 |
Why?
| | Virus Latency | 4 | 2014 | 84 | 0.840 |
Why?
| | Respiratory Syncytial Virus, Human | 3 | 2019 | 69 | 0.830 |
Why?
| | CD8-Positive T-Lymphocytes | 5 | 2018 | 855 | 0.820 |
Why?
| | Immune Sera | 4 | 2020 | 87 | 0.820 |
Why?
| | B-Lymphocytes | 9 | 2021 | 816 | 0.810 |
Why?
| | Injections, Intramuscular | 5 | 2022 | 115 | 0.800 |
Why?
| | Pneumococcal Vaccines | 3 | 2021 | 141 | 0.800 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 22 | 2021 | 836 | 0.780 |
Why?
| | Influenza A Virus, H1N1 Subtype | 6 | 2017 | 146 | 0.760 |
Why?
| | Antibodies, Neutralizing | 12 | 2023 | 265 | 0.760 |
Why?
| | Age Factors | 17 | 2021 | 3161 | 0.750 |
Why?
| | Antibodies, Protozoan | 3 | 2007 | 32 | 0.750 |
Why?
| | Respiratory Syncytial Virus Vaccines | 2 | 2019 | 34 | 0.750 |
Why?
| | Drug Resistance, Viral | 7 | 2009 | 110 | 0.740 |
Why?
| | Rotavirus Infections | 3 | 2017 | 45 | 0.730 |
Why?
| | Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 6 | 2017 | 15 | 0.730 |
Why?
| | Influenza B virus | 6 | 2012 | 37 | 0.700 |
Why?
| | Vaccination Coverage | 2 | 2018 | 79 | 0.690 |
Why?
| | Anti-Retroviral Agents | 5 | 2018 | 231 | 0.690 |
Why?
| | Adult | 76 | 2024 | 35634 | 0.660 |
Why?
| | Rotavirus Vaccines | 2 | 2017 | 49 | 0.660 |
Why?
| | Infectious Disease Transmission, Vertical | 7 | 2020 | 171 | 0.660 |
Why?
| | Down Syndrome | 2 | 2023 | 478 | 0.650 |
Why?
| | Adenovirus Infections, Human | 4 | 2015 | 15 | 0.650 |
Why?
| | Receptors, Adrenergic, beta-1 | 3 | 2007 | 46 | 0.650 |
Why?
| | Clinical Trials as Topic | 15 | 2019 | 1005 | 0.630 |
Why?
| | Th1 Cells | 3 | 2018 | 137 | 0.620 |
Why?
| | Child, Preschool | 42 | 2024 | 10522 | 0.610 |
Why?
| | HIV | 4 | 2010 | 227 | 0.600 |
Why?
| | Insurance Claim Review | 1 | 2019 | 64 | 0.600 |
Why?
| | AIDS-Related Opportunistic Infections | 4 | 2015 | 123 | 0.600 |
Why?
| | Influenza A Virus, H3N2 Subtype | 4 | 2017 | 43 | 0.590 |
Why?
| | Cytomegalovirus Infections | 4 | 2015 | 190 | 0.590 |
Why?
| | CD4 Lymphocyte Count | 14 | 2017 | 267 | 0.590 |
Why?
| | Alphapapillomavirus | 4 | 2016 | 39 | 0.590 |
Why?
| | Infant | 31 | 2023 | 9018 | 0.580 |
Why?
| | Child | 59 | 2024 | 20962 | 0.570 |
Why?
| | Dose-Response Relationship, Immunologic | 3 | 2016 | 82 | 0.560 |
Why?
| | Anti-HIV Agents | 6 | 2015 | 757 | 0.560 |
Why?
| | Trypanosoma cruzi | 4 | 2007 | 25 | 0.560 |
Why?
| | Virus Shedding | 6 | 2017 | 48 | 0.560 |
Why?
| | Pneumonia | 1 | 2023 | 619 | 0.550 |
Why?
| | Health Expenditures | 1 | 2019 | 180 | 0.540 |
Why?
| | Adolescent | 53 | 2024 | 20451 | 0.540 |
Why?
| | Antibody Formation | 7 | 2023 | 291 | 0.540 |
Why?
| | Herpesviridae Infections | 4 | 2015 | 142 | 0.530 |
Why?
| | Infant, Premature | 5 | 2020 | 541 | 0.530 |
Why?
| | Cytosine | 3 | 2015 | 49 | 0.530 |
Why?
| | Interleukin-2 | 7 | 2022 | 437 | 0.530 |
Why?
| | Pain | 6 | 2022 | 791 | 0.510 |
Why?
| | Organophosphonates | 2 | 2015 | 92 | 0.510 |
Why?
| | Antigens, Viral | 21 | 2017 | 179 | 0.510 |
Why?
| | Cytomegalovirus | 7 | 2006 | 154 | 0.500 |
Why?
| | Injections, Subcutaneous | 1 | 2016 | 146 | 0.500 |
Why?
| | Immunoglobulin G | 9 | 2021 | 851 | 0.490 |
Why?
| | Guanine | 14 | 2006 | 76 | 0.490 |
Why?
| | Enzyme-Linked Immunospot Assay | 4 | 2018 | 36 | 0.480 |
Why?
| | Health Care Costs | 1 | 2018 | 367 | 0.480 |
Why?
| | Refrigeration | 2 | 2018 | 11 | 0.480 |
Why?
| | Uterine Cervical Neoplasms | 5 | 2016 | 230 | 0.470 |
Why?
| | Follow-Up Studies | 21 | 2019 | 4896 | 0.470 |
Why?
| | Ribosomal Proteins | 2 | 2006 | 77 | 0.470 |
Why?
| | Viral Load | 12 | 2018 | 449 | 0.470 |
Why?
| | Polyomavirus Infections | 1 | 2015 | 28 | 0.470 |
Why?
| | Immunity, Humoral | 3 | 2021 | 118 | 0.460 |
Why?
| | Skin Diseases | 1 | 2016 | 143 | 0.450 |
Why?
| | Oropharynx | 1 | 2014 | 45 | 0.450 |
Why?
| | Herpes Genitalis | 7 | 2014 | 16 | 0.450 |
Why?
| | Blood | 1 | 2014 | 105 | 0.440 |
Why?
| | Infant, Newborn | 28 | 2023 | 5772 | 0.440 |
Why?
| | Polymerase Chain Reaction | 10 | 2019 | 1033 | 0.420 |
Why?
| | Immunogenicity, Vaccine | 4 | 2022 | 27 | 0.420 |
Why?
| | Immunization | 4 | 2014 | 411 | 0.420 |
Why?
| | Vaccines | 3 | 2018 | 400 | 0.410 |
Why?
| | Time Factors | 20 | 2021 | 6550 | 0.410 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2016 | 373 | 0.410 |
Why?
| | Herpes Labialis | 3 | 2013 | 8 | 0.400 |
Why?
| | Trigeminal Ganglion | 2 | 2003 | 25 | 0.400 |
Why?
| | Placebos | 8 | 2017 | 201 | 0.400 |
Why?
| | Aging | 10 | 2017 | 1774 | 0.400 |
Why?
| | Retrospective Studies | 16 | 2023 | 14553 | 0.390 |
Why?
| | Young Adult | 24 | 2023 | 12467 | 0.390 |
Why?
| | Post-Exposure Prophylaxis | 2 | 2023 | 8 | 0.380 |
Why?
| | RNA, Viral | 21 | 2018 | 620 | 0.380 |
Why?
| | Sensory Receptor Cells | 1 | 2012 | 103 | 0.380 |
Why?
| | United States | 17 | 2023 | 13913 | 0.370 |
Why?
| | Communicable Diseases | 1 | 2014 | 152 | 0.370 |
Why?
| | Randomized Controlled Trials as Topic | 7 | 2021 | 1368 | 0.370 |
Why?
| | Quality of Life | 7 | 2021 | 2695 | 0.360 |
Why?
| | Pregnancy | 20 | 2020 | 6423 | 0.340 |
Why?
| | Databases, Factual | 4 | 2019 | 1269 | 0.340 |
Why?
| | Human papillomavirus 18 | 5 | 2018 | 15 | 0.340 |
Why?
| | Human papillomavirus 16 | 5 | 2018 | 34 | 0.330 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2012 | 221 | 0.330 |
Why?
| | Glycoproteins | 2 | 2023 | 338 | 0.330 |
Why?
| | Cost-Benefit Analysis | 4 | 2024 | 569 | 0.320 |
Why?
| | Poverty | 1 | 2013 | 499 | 0.320 |
Why?
| | Risk Factors | 20 | 2023 | 9801 | 0.320 |
Why?
| | Vaccines, Subunit | 5 | 2021 | 48 | 0.310 |
Why?
| | Treatment Outcome | 19 | 2016 | 10241 | 0.310 |
Why?
| | Frail Elderly | 2 | 2020 | 120 | 0.310 |
Why?
| | Immune Reconstitution Inflammatory Syndrome | 1 | 2009 | 18 | 0.310 |
Why?
| | Activities of Daily Living | 3 | 2021 | 384 | 0.290 |
Why?
| | Varicella Zoster Virus Infection | 2 | 2018 | 25 | 0.290 |
Why?
| | Meningitis, Viral | 3 | 1997 | 21 | 0.280 |
Why?
| | Hemagglutination Inhibition Tests | 7 | 2017 | 38 | 0.280 |
Why?
| | Meningitis | 1 | 2008 | 79 | 0.280 |
Why?
| | Seasons | 3 | 2023 | 493 | 0.280 |
Why?
| | Research Design | 2 | 2013 | 1045 | 0.270 |
Why?
| | Animals | 33 | 2021 | 35409 | 0.270 |
Why?
| | Viremia | 5 | 2018 | 132 | 0.270 |
Why?
| | Viral Plaque Assay | 8 | 2012 | 29 | 0.270 |
Why?
| | Cells, Cultured | 19 | 2012 | 4102 | 0.270 |
Why?
| | Cytokines | 7 | 2018 | 2022 | 0.270 |
Why?
| | Neurons | 6 | 2003 | 1509 | 0.260 |
Why?
| | Neoplasms | 3 | 2016 | 2454 | 0.260 |
Why?
| | Respiratory Syncytial Virus Infections | 3 | 2017 | 120 | 0.250 |
Why?
| | Immunocompetence | 4 | 2019 | 42 | 0.250 |
Why?
| | Prospective Studies | 24 | 2019 | 7158 | 0.250 |
Why?
| | Protozoan Proteins | 1 | 2006 | 75 | 0.250 |
Why?
| | Sleep Wake Disorders | 4 | 2013 | 255 | 0.240 |
Why?
| | Nucleic Acid Hybridization | 11 | 2006 | 188 | 0.240 |
Why?
| | Virus Replication | 12 | 2018 | 453 | 0.240 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 4 | 2017 | 253 | 0.240 |
Why?
| | Recurrence | 13 | 2019 | 1013 | 0.240 |
Why?
| | Severity of Illness Index | 14 | 2015 | 2739 | 0.230 |
Why?
| | Autoantibodies | 2 | 2007 | 1468 | 0.230 |
Why?
| | Cross Reactions | 6 | 2014 | 133 | 0.230 |
Why?
| | Nucleosides | 1 | 2004 | 27 | 0.230 |
Why?
| | Cell Count | 2 | 2005 | 318 | 0.230 |
Why?
| | Intestines | 2 | 2018 | 350 | 0.230 |
Why?
| | Viral Proteins | 5 | 2018 | 327 | 0.230 |
Why?
| | Vaccine Potency | 3 | 2019 | 6 | 0.230 |
Why?
| | Influenza A virus | 5 | 2012 | 100 | 0.230 |
Why?
| | Health Resources | 2 | 2019 | 115 | 0.230 |
Why?
| | Depressive Disorder, Major | 4 | 2013 | 345 | 0.220 |
Why?
| | Nonlinear Dynamics | 1 | 2005 | 88 | 0.220 |
Why?
| | Interferons | 9 | 1982 | 189 | 0.220 |
Why?
| | Phosphoproteins | 1 | 2006 | 333 | 0.220 |
Why?
| | Herpesvirus 4, Human | 3 | 2014 | 157 | 0.220 |
Why?
| | Monocytes | 7 | 2005 | 554 | 0.220 |
Why?
| | Cholecalciferol | 1 | 2024 | 56 | 0.210 |
Why?
| | Neuralgia | 4 | 2010 | 128 | 0.210 |
Why?
| | Genetic Variation | 1 | 2008 | 937 | 0.210 |
Why?
| | Long-Term Care | 1 | 2024 | 92 | 0.210 |
Why?
| | Immunoassay | 2 | 2017 | 108 | 0.210 |
Why?
| | Antibody Affinity | 2 | 2021 | 59 | 0.210 |
Why?
| | Cricetinae | 6 | 2007 | 280 | 0.200 |
Why?
| | Enterovirus Infections | 5 | 1995 | 171 | 0.200 |
Why?
| | Encephalitis | 2 | 1995 | 131 | 0.200 |
Why?
| | Ganglia, Spinal | 2 | 1993 | 75 | 0.200 |
Why?
| | Developing Countries | 2 | 2016 | 284 | 0.200 |
Why?
| | Drug Combinations | 2 | 2022 | 331 | 0.200 |
Why?
| | CHO Cells | 3 | 2007 | 155 | 0.200 |
Why?
| | Pain Measurement | 8 | 2019 | 510 | 0.190 |
Why?
| | Lymphocyte Activation | 13 | 2015 | 1110 | 0.190 |
Why?
| | Papillomaviridae | 3 | 2011 | 112 | 0.190 |
Why?
| | Virus Activation | 4 | 2010 | 88 | 0.190 |
Why?
| | Lymphocytosis | 1 | 2021 | 10 | 0.190 |
Why?
| | Longitudinal Studies | 8 | 2018 | 2724 | 0.190 |
Why?
| | Immunosenescence | 1 | 2021 | 4 | 0.180 |
Why?
| | Fetal Diseases | 4 | 1991 | 164 | 0.180 |
Why?
| | Fibroblasts | 10 | 2018 | 954 | 0.180 |
Why?
| | Cell Separation | 1 | 2002 | 316 | 0.180 |
Why?
| | Virology | 1 | 2001 | 23 | 0.180 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2021 | 66 | 0.180 |
Why?
| | Herpes Simplex Virus Vaccines | 2 | 2012 | 4 | 0.180 |
Why?
| | Case-Control Studies | 5 | 2018 | 3384 | 0.180 |
Why?
| | Fluorescent Antibody Technique | 6 | 2016 | 377 | 0.180 |
Why?
| | Cell Line | 16 | 2018 | 2780 | 0.170 |
Why?
| | Vitamin D | 1 | 2024 | 380 | 0.170 |
Why?
| | HIV-1 | 5 | 2018 | 839 | 0.170 |
Why?
| | Health Services for the Aged | 1 | 2001 | 72 | 0.170 |
Why?
| | Immunoglobulin A | 3 | 2017 | 201 | 0.170 |
Why?
| | Cohort Studies | 10 | 2022 | 5444 | 0.170 |
Why?
| | Enterovirus | 3 | 1995 | 78 | 0.170 |
Why?
| | Laboratories | 1 | 2001 | 109 | 0.170 |
Why?
| | Antidepressive Agents | 2 | 2013 | 229 | 0.170 |
Why?
| | Acquired Immunodeficiency Syndrome | 2 | 1993 | 228 | 0.160 |
Why?
| | Myocytes, Cardiac | 1 | 2004 | 499 | 0.160 |
Why?
| | Dietary Supplements | 1 | 2024 | 532 | 0.160 |
Why?
| | Leukocytes, Mononuclear | 5 | 2010 | 546 | 0.160 |
Why?
| | Immunization, Passive | 4 | 1994 | 86 | 0.160 |
Why?
| | Immunoenzyme Techniques | 3 | 2006 | 211 | 0.160 |
Why?
| | Hemophilia A | 2 | 1993 | 115 | 0.160 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2022 | 250 | 0.160 |
Why?
| | Immunization Schedule | 3 | 2016 | 197 | 0.160 |
Why?
| | Pneumococcal Infections | 2 | 2013 | 112 | 0.160 |
Why?
| | Cholera Toxin | 1 | 2018 | 30 | 0.150 |
Why?
| | Infant, Premature, Diseases | 3 | 1995 | 93 | 0.150 |
Why?
| | Autophagosomes | 1 | 2018 | 19 | 0.150 |
Why?
| | Microbial Sensitivity Tests | 8 | 2005 | 349 | 0.150 |
Why?
| | Mice | 9 | 2021 | 16983 | 0.150 |
Why?
| | Liver Transplantation | 1 | 2006 | 833 | 0.150 |
Why?
| | Age Distribution | 3 | 2016 | 372 | 0.150 |
Why?
| | Sex Distribution | 3 | 2016 | 359 | 0.150 |
Why?
| | Lymphocytes | 8 | 1998 | 377 | 0.150 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2018 | 68 | 0.150 |
Why?
| | Viral Fusion Proteins | 1 | 2017 | 17 | 0.140 |
Why?
| | Immune Evasion | 1 | 2018 | 54 | 0.140 |
Why?
| | Drug Therapy, Combination | 4 | 2016 | 1042 | 0.140 |
Why?
| | Simian virus 40 | 11 | 1977 | 23 | 0.140 |
Why?
| | Regression Analysis | 2 | 2019 | 998 | 0.140 |
Why?
| | Genes, Viral | 2 | 2006 | 82 | 0.140 |
Why?
| | Lysosomes | 1 | 2018 | 137 | 0.140 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2017 | 72 | 0.140 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2017 | 51 | 0.140 |
Why?
| | Multivariate Analysis | 2 | 2018 | 1501 | 0.140 |
Why?
| | Disease Transmission, Infectious | 1 | 2018 | 55 | 0.140 |
Why?
| | Cryopreservation | 1 | 2018 | 94 | 0.140 |
Why?
| | Lysosomal-Associated Membrane Protein 1 | 1 | 2017 | 6 | 0.140 |
Why?
| | Cost of Illness | 5 | 2014 | 277 | 0.140 |
Why?
| | Protein Subunits | 1 | 2018 | 233 | 0.140 |
Why?
| | Models, Biological | 1 | 2005 | 1724 | 0.140 |
Why?
| | Cell Division | 5 | 2003 | 790 | 0.140 |
Why?
| | Depression | 3 | 2013 | 1323 | 0.140 |
Why?
| | Observational Studies as Topic | 1 | 2017 | 110 | 0.130 |
Why?
| | Adverse Drug Reaction Reporting Systems | 1 | 2017 | 74 | 0.130 |
Why?
| | Recombinant Proteins | 2 | 2018 | 1311 | 0.130 |
Why?
| | Infectious Mononucleosis | 2 | 1991 | 9 | 0.130 |
Why?
| | Receptors, Muscarinic | 1 | 1996 | 20 | 0.130 |
Why?
| | Infusions, Intravenous | 2 | 2016 | 402 | 0.130 |
Why?
| | Africa | 1 | 2017 | 99 | 0.130 |
Why?
| | Antibodies, Bacterial | 3 | 2013 | 139 | 0.130 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 1996 | 46 | 0.130 |
Why?
| | Foscarnet | 3 | 2003 | 19 | 0.130 |
Why?
| | Comorbidity | 3 | 2019 | 1551 | 0.130 |
Why?
| | Frailty | 1 | 2019 | 152 | 0.130 |
Why?
| | Nelfinavir | 1 | 2016 | 9 | 0.130 |
Why?
| | Latex Fixation Tests | 1 | 1996 | 3 | 0.130 |
Why?
| | Erythema | 1 | 2016 | 28 | 0.130 |
Why?
| | Lopinavir | 1 | 2016 | 30 | 0.130 |
Why?
| | Atazanavir Sulfate | 1 | 2016 | 41 | 0.130 |
Why?
| | Autophagy | 1 | 2018 | 266 | 0.120 |
Why?
| | Hospitalization | 2 | 2023 | 2079 | 0.120 |
Why?
| | Peptide Fragments | 3 | 2007 | 695 | 0.120 |
Why?
| | Ribavirin | 2 | 1994 | 91 | 0.120 |
Why?
| | HIV Protease Inhibitors | 1 | 2016 | 68 | 0.120 |
Why?
| | Ritonavir | 1 | 2016 | 73 | 0.120 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2015 | 577 | 0.120 |
Why?
| | Dipeptides | 1 | 2015 | 48 | 0.120 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2018 | 398 | 0.120 |
Why?
| | Bone Marrow Transplantation | 3 | 1990 | 277 | 0.120 |
Why?
| | Chronic Disease | 6 | 2019 | 1724 | 0.120 |
Why?
| | Antibodies, Monoclonal | 1 | 2022 | 1368 | 0.120 |
Why?
| | Lymphocyte Subsets | 1 | 2015 | 84 | 0.120 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2017 | 232 | 0.120 |
Why?
| | Global Health | 1 | 2018 | 329 | 0.120 |
Why?
| | Data Interpretation, Statistical | 3 | 2019 | 338 | 0.120 |
Why?
| | Genotype | 3 | 2008 | 1829 | 0.120 |
Why?
| | BK Virus | 1 | 2015 | 14 | 0.120 |
Why?
| | Host-Pathogen Interactions | 1 | 2018 | 355 | 0.120 |
Why?
| | Brain Stem | 1 | 1995 | 100 | 0.120 |
Why?
| | Guatemala | 1 | 2016 | 314 | 0.120 |
Why?
| | Molecular Sequence Data | 5 | 2006 | 2833 | 0.120 |
Why?
| | Propylene Glycols | 1 | 2015 | 27 | 0.120 |
Why?
| | Reproducibility of Results | 5 | 2013 | 3089 | 0.120 |
Why?
| | Survival Rate | 3 | 2016 | 1872 | 0.120 |
Why?
| | Base Sequence | 8 | 2007 | 2142 | 0.120 |
Why?
| | Medication Reconciliation | 1 | 2015 | 29 | 0.120 |
Why?
| | Sphingosine | 1 | 2015 | 40 | 0.110 |
Why?
| | Transfusion Reaction | 1 | 1995 | 43 | 0.110 |
Why?
| | Infant, Newborn, Diseases | 1 | 2016 | 111 | 0.110 |
Why?
| | Maus Elberfeld virus | 2 | 1991 | 5 | 0.110 |
Why?
| | Immunity, Mucosal | 2 | 2012 | 94 | 0.110 |
Why?
| | Respiratory Syncytial Viruses | 4 | 1993 | 52 | 0.110 |
Why?
| | Chlamydia trachomatis | 2 | 1991 | 46 | 0.110 |
Why?
| | Histocompatibility Antigens Class I | 1 | 1996 | 200 | 0.110 |
Why?
| | Maternal-Fetal Exchange | 3 | 1995 | 162 | 0.110 |
Why?
| | Clinical Trials, Phase III as Topic | 3 | 2021 | 94 | 0.110 |
Why?
| | Hemagglutinins, Viral | 1 | 1994 | 6 | 0.110 |
Why?
| | Lymphoma | 1 | 2015 | 198 | 0.110 |
Why?
| | Laryngeal Diseases | 1 | 1994 | 29 | 0.110 |
Why?
| | DNA-Directed DNA Polymerase | 2 | 1992 | 44 | 0.110 |
Why?
| | Needs Assessment | 1 | 2016 | 357 | 0.110 |
Why?
| | Analgesics | 3 | 2010 | 194 | 0.110 |
Why?
| | Feces | 1 | 2017 | 442 | 0.110 |
Why?
| | Autoantigens | 1 | 1996 | 420 | 0.110 |
Why?
| | Placenta | 2 | 1991 | 716 | 0.110 |
Why?
| | Lamivudine | 2 | 2015 | 61 | 0.110 |
Why?
| | Zidovudine | 2 | 2015 | 78 | 0.110 |
Why?
| | Immunoglobulins, Intravenous | 5 | 1995 | 130 | 0.110 |
Why?
| | Cross-Over Studies | 2 | 2013 | 521 | 0.110 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2013 | 27 | 0.110 |
Why?
| | Practice Guidelines as Topic | 2 | 2017 | 1514 | 0.100 |
Why?
| | Health Status | 2 | 2010 | 758 | 0.100 |
Why?
| | Anti-Inflammatory Agents | 3 | 2013 | 482 | 0.100 |
Why?
| | Ethics, Research | 1 | 2013 | 31 | 0.100 |
Why?
| | Research Subjects | 1 | 2013 | 42 | 0.100 |
Why?
| | Autoimmune Diseases | 1 | 1996 | 428 | 0.100 |
Why?
| | RNA Probes | 2 | 1991 | 13 | 0.100 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2014 | 186 | 0.100 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1996 | 279 | 0.100 |
Why?
| | Risk Assessment | 4 | 2016 | 3269 | 0.100 |
Why?
| | Chagas Cardiomyopathy | 2 | 2007 | 22 | 0.100 |
Why?
| | Killer Cells, Natural | 1 | 1996 | 426 | 0.100 |
Why?
| | Measles Vaccine | 1 | 2012 | 19 | 0.100 |
Why?
| | Picornaviridae Infections | 2 | 1990 | 45 | 0.100 |
Why?
| | Indoles | 1 | 2015 | 387 | 0.100 |
Why?
| | Gene Expression Regulation, Viral | 1 | 2012 | 90 | 0.100 |
Why?
| | Colorado | 4 | 2018 | 4410 | 0.100 |
Why?
| | Human papillomavirus 31 | 1 | 2011 | 1 | 0.100 |
Why?
| | Drug Resistance, Microbial | 4 | 2001 | 69 | 0.100 |
Why?
| | Ureaplasma urealyticum | 1 | 1991 | 3 | 0.090 |
Why?
| | Immunosuppressive Agents | 3 | 2015 | 858 | 0.090 |
Why?
| | Flow Cytometry | 5 | 2017 | 1160 | 0.090 |
Why?
| | Meningitis, Aseptic | 1 | 1991 | 13 | 0.090 |
Why?
| | T-Lymphocytes, Cytotoxic | 2 | 2011 | 170 | 0.090 |
Why?
| | Insurance, Health | 1 | 2014 | 269 | 0.090 |
Why?
| | Mutation | 5 | 2009 | 3706 | 0.090 |
Why?
| | Efficiency | 1 | 2012 | 92 | 0.090 |
Why?
| | Chorioamnionitis | 1 | 1991 | 40 | 0.090 |
Why?
| | Myocardium | 1 | 1996 | 983 | 0.090 |
Why?
| | Neurogenesis | 1 | 2012 | 126 | 0.090 |
Why?
| | Linear Models | 2 | 2010 | 822 | 0.090 |
Why?
| | Macrophages | 3 | 2005 | 1489 | 0.090 |
Why?
| | Cytotoxicity Tests, Immunologic | 2 | 1996 | 41 | 0.090 |
Why?
| | Neural Stem Cells | 1 | 2012 | 142 | 0.090 |
Why?
| | Gastroenteritis | 2 | 1989 | 67 | 0.090 |
Why?
| | Health Services Accessibility | 1 | 2018 | 903 | 0.090 |
Why?
| | Drug Design | 1 | 2012 | 158 | 0.090 |
Why?
| | Epidemiological Monitoring | 3 | 2018 | 50 | 0.090 |
Why?
| | Sensitivity and Specificity | 3 | 2009 | 1847 | 0.090 |
Why?
| | Adjuvants, Pharmaceutic | 2 | 2022 | 10 | 0.090 |
Why?
| | Cervix Uteri | 1 | 2010 | 49 | 0.090 |
Why?
| | Exanthema | 1 | 2011 | 74 | 0.090 |
Why?
| | Serum | 1 | 2010 | 58 | 0.090 |
Why?
| | Adenoviridae | 9 | 2005 | 193 | 0.090 |
Why?
| | Herpesviridae | 2 | 1981 | 22 | 0.080 |
Why?
| | Antidepressive Agents, Tricyclic | 1 | 2010 | 30 | 0.080 |
Why?
| | Herpesvirus Vaccines | 1 | 2010 | 4 | 0.080 |
Why?
| | Rats | 3 | 2006 | 5487 | 0.080 |
Why?
| | Antigen-Presenting Cells | 5 | 2010 | 151 | 0.080 |
Why?
| | Immunoglobulin M | 1 | 1991 | 276 | 0.080 |
Why?
| | Enterovirus B, Human | 2 | 1988 | 25 | 0.080 |
Why?
| | Respiratory Tract Infections | 1 | 1994 | 376 | 0.080 |
Why?
| | Pilot Projects | 1 | 2015 | 1597 | 0.080 |
Why?
| | Medicaid | 1 | 2014 | 433 | 0.080 |
Why?
| | Surveys and Questionnaires | 7 | 2021 | 5437 | 0.080 |
Why?
| | Dermatomyositis | 1 | 1989 | 26 | 0.080 |
Why?
| | Epitopes | 3 | 2004 | 474 | 0.080 |
Why?
| | Poliovirus | 2 | 2001 | 82 | 0.080 |
Why?
| | Receptors, Virus | 2 | 2006 | 82 | 0.080 |
Why?
| | Hepatitis B Vaccines | 1 | 2009 | 47 | 0.080 |
Why?
| | Placenta Diseases | 1 | 1989 | 15 | 0.080 |
Why?
| | Protozoan Infections | 1 | 1989 | 10 | 0.080 |
Why?
| | DNA Primers | 2 | 2009 | 508 | 0.080 |
Why?
| | Drug Stability | 1 | 2009 | 161 | 0.080 |
Why?
| | Thymidine Kinase | 4 | 2001 | 15 | 0.080 |
Why?
| | Skin Diseases, Viral | 1 | 2008 | 5 | 0.080 |
Why?
| | Geriatrics | 1 | 2010 | 81 | 0.080 |
Why?
| | Oligonucleotide Probes | 1 | 1988 | 49 | 0.080 |
Why?
| | Vagina | 1 | 2010 | 174 | 0.080 |
Why?
| | Immunologic Deficiency Syndromes | 2 | 1986 | 64 | 0.080 |
Why?
| | Geriatric Assessment | 1 | 2010 | 205 | 0.070 |
Why?
| | Species Specificity | 2 | 2006 | 568 | 0.070 |
Why?
| | Muscles | 1 | 1989 | 320 | 0.070 |
Why?
| | Amino Acid Sequence | 2 | 2006 | 2057 | 0.070 |
Why?
| | Hydrocortisone | 1 | 2010 | 306 | 0.070 |
Why?
| | Interferon Type I | 1 | 1989 | 139 | 0.070 |
Why?
| | Administration, Intranasal | 1 | 2008 | 84 | 0.070 |
Why?
| | Kinetics | 2 | 2010 | 1645 | 0.070 |
Why?
| | Poisson Distribution | 2 | 2005 | 73 | 0.070 |
Why?
| | In Vitro Techniques | 6 | 2003 | 1092 | 0.070 |
Why?
| | Anticonvulsants | 1 | 2010 | 209 | 0.070 |
Why?
| | Sequence Alignment | 1 | 2008 | 331 | 0.070 |
Why?
| | Picornaviridae | 1 | 1988 | 17 | 0.070 |
Why?
| | Lipid A | 2 | 2018 | 29 | 0.070 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 1988 | 27 | 0.070 |
Why?
| | Pertussis Vaccine | 1 | 2007 | 21 | 0.070 |
Why?
| | Evidence-Based Practice | 1 | 2010 | 212 | 0.070 |
Why?
| | Prevalence | 4 | 2018 | 2564 | 0.070 |
Why?
| | Spinal Cord | 2 | 2001 | 355 | 0.070 |
Why?
| | Immunosorbent Techniques | 1 | 2007 | 20 | 0.070 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 1996 | 1560 | 0.070 |
Why?
| | Quality-Adjusted Life Years | 1 | 2007 | 106 | 0.070 |
Why?
| | Pregnancy Outcome | 1 | 2010 | 392 | 0.070 |
Why?
| | Veterans | 1 | 2018 | 1383 | 0.070 |
Why?
| | Acute Kidney Injury | 1 | 2015 | 791 | 0.070 |
Why?
| | Data Collection | 1 | 2010 | 653 | 0.070 |
Why?
| | Cricetulus | 1 | 2007 | 107 | 0.070 |
Why?
| | Public Health | 1 | 2012 | 487 | 0.070 |
Why?
| | Receptor, IGF Type 2 | 1 | 2006 | 6 | 0.070 |
Why?
| | Vero Cells | 1 | 2006 | 66 | 0.070 |
Why?
| | Inhibitory Concentration 50 | 1 | 2006 | 86 | 0.070 |
Why?
| | COS Cells | 1 | 2007 | 186 | 0.070 |
Why?
| | Research | 1 | 2010 | 420 | 0.070 |
Why?
| | Heparitin Sulfate | 1 | 2006 | 42 | 0.070 |
Why?
| | Opportunistic Infections | 3 | 1993 | 46 | 0.070 |
Why?
| | Immunoglobulin Fragments | 1 | 2006 | 11 | 0.070 |
Why?
| | Neutralization Tests | 5 | 2012 | 73 | 0.070 |
Why?
| | NIH 3T3 Cells | 1 | 2006 | 140 | 0.060 |
Why?
| | Administration, Topical | 4 | 2013 | 147 | 0.060 |
Why?
| | Drug Administration Schedule | 2 | 2021 | 766 | 0.060 |
Why?
| | Kaplan-Meier Estimate | 3 | 2016 | 851 | 0.060 |
Why?
| | Random Allocation | 6 | 1992 | 347 | 0.060 |
Why?
| | Immunoglobulin Variable Region | 1 | 2006 | 79 | 0.060 |
Why?
| | Cyclic AMP | 1 | 2007 | 238 | 0.060 |
Why?
| | Meningococcal Vaccines | 1 | 2006 | 54 | 0.060 |
Why?
| | Pneumonia, Viral | 2 | 1990 | 342 | 0.060 |
Why?
| | Logistic Models | 2 | 2010 | 1989 | 0.060 |
Why?
| | Nasopharyngeal Diseases | 1 | 1985 | 5 | 0.060 |
Why?
| | Hybridization, Genetic | 9 | 1974 | 73 | 0.060 |
Why?
| | Bone Marrow | 2 | 1984 | 272 | 0.060 |
Why?
| | Endocytosis | 1 | 2006 | 162 | 0.060 |
Why?
| | Motor Activity | 1 | 2010 | 684 | 0.060 |
Why?
| | Proportional Hazards Models | 1 | 2009 | 1199 | 0.060 |
Why?
| | Antineoplastic Agents | 2 | 2016 | 2045 | 0.060 |
Why?
| | Flaviviridae Infections | 1 | 2005 | 1 | 0.060 |
Why?
| | GB virus C | 1 | 2005 | 1 | 0.060 |
Why?
| | Hepatitis, Viral, Human | 1 | 2005 | 25 | 0.060 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2006 | 541 | 0.060 |
Why?
| | Cell Differentiation | 1 | 2012 | 1900 | 0.060 |
Why?
| | Normal Distribution | 1 | 2005 | 21 | 0.060 |
Why?
| | Uterine Cervical Dysplasia | 2 | 2016 | 40 | 0.060 |
Why?
| | HLA Antigens | 3 | 1987 | 235 | 0.060 |
Why?
| | Evaluation Studies as Topic | 3 | 1996 | 176 | 0.060 |
Why?
| | Organ Transplantation | 1 | 2008 | 228 | 0.060 |
Why?
| | Autopsy | 2 | 2001 | 92 | 0.060 |
Why?
| | Transfection | 1 | 2007 | 918 | 0.060 |
Why?
| | Disease Outbreaks | 1 | 1988 | 349 | 0.060 |
Why?
| | Neurons, Afferent | 1 | 2005 | 101 | 0.060 |
Why?
| | Cell Culture Techniques | 1 | 2006 | 349 | 0.060 |
Why?
| | Risk | 3 | 2016 | 860 | 0.060 |
Why?
| | Receptors, Cholinergic | 1 | 2004 | 38 | 0.060 |
Why?
| | Macaca radiata | 2 | 2001 | 16 | 0.060 |
Why?
| | Epitope Mapping | 1 | 2004 | 58 | 0.060 |
Why?
| | Mental Health | 1 | 2010 | 691 | 0.050 |
Why?
| | Cell Adhesion Molecules | 1 | 2005 | 173 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2015 | 2016 | 0.050 |
Why?
| | Sex Factors | 2 | 2003 | 1973 | 0.050 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 2003 | 66 | 0.050 |
Why?
| | Abdominal Neoplasms | 1 | 2003 | 34 | 0.050 |
Why?
| | Receptors, Adrenergic, beta | 1 | 2004 | 127 | 0.050 |
Why?
| | Demography | 2 | 2018 | 279 | 0.050 |
Why?
| | Receptors, Cell Surface | 1 | 2005 | 381 | 0.050 |
Why?
| | Multicenter Studies as Topic | 2 | 2001 | 287 | 0.050 |
Why?
| | RNA | 2 | 1988 | 877 | 0.050 |
Why?
| | 2-Aminopurine | 2 | 2007 | 9 | 0.050 |
Why?
| | Membrane Glycoproteins | 1 | 2005 | 477 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2009 | 2062 | 0.050 |
Why?
| | Adaptive Immunity | 2 | 2017 | 161 | 0.050 |
Why?
| | Neuroblastoma | 1 | 2003 | 151 | 0.050 |
Why?
| | Poliomyelitis | 2 | 2001 | 36 | 0.050 |
Why?
| | Heart Rate | 1 | 2006 | 804 | 0.050 |
Why?
| | Forecasting | 3 | 2010 | 361 | 0.050 |
Why?
| | Blotting, Western | 2 | 2015 | 1204 | 0.050 |
Why?
| | Cell Nucleus | 3 | 1991 | 590 | 0.050 |
Why?
| | Hepatitis C | 1 | 2004 | 244 | 0.050 |
Why?
| | Gene Expression | 1 | 2006 | 1465 | 0.050 |
Why?
| | Genome, Viral | 1 | 2002 | 128 | 0.050 |
Why?
| | Spondylarthropathies | 1 | 2021 | 6 | 0.050 |
Why?
| | Respirovirus Infections | 2 | 1991 | 23 | 0.050 |
Why?
| | Poliovirus Vaccine, Oral | 1 | 2001 | 25 | 0.050 |
Why?
| | Secondary Prevention | 2 | 2013 | 220 | 0.040 |
Why?
| | Heart Transplantation | 1 | 2007 | 722 | 0.040 |
Why?
| | Peripheral Nerves | 1 | 2001 | 70 | 0.040 |
Why?
| | Fatal Outcome | 1 | 2001 | 300 | 0.040 |
Why?
| | Sex Characteristics | 2 | 2017 | 735 | 0.040 |
Why?
| | Sleep | 1 | 2006 | 689 | 0.040 |
Why?
| | Virion | 1 | 2001 | 84 | 0.040 |
Why?
| | Psoriasis | 1 | 2021 | 87 | 0.040 |
Why?
| | Canada | 2 | 2012 | 353 | 0.040 |
Why?
| | Amniotic Fluid | 3 | 1991 | 87 | 0.040 |
Why?
| | Enterotoxins | 2 | 1994 | 87 | 0.040 |
Why?
| | Rats, Sprague-Dawley | 1 | 2004 | 2403 | 0.040 |
Why?
| | Hematopoietic Stem Cells | 1 | 1982 | 382 | 0.040 |
Why?
| | Saliva | 2 | 2010 | 212 | 0.040 |
Why?
| | Saponins | 1 | 2018 | 8 | 0.040 |
Why?
| | Haptoglobins | 1 | 2018 | 53 | 0.040 |
Why?
| | Seroconversion | 1 | 2018 | 46 | 0.040 |
Why?
| | Encephalitis, Viral | 1 | 1998 | 43 | 0.040 |
Why?
| | Drug Compounding | 1 | 2018 | 97 | 0.040 |
Why?
| | Protein Precursors | 1 | 2018 | 128 | 0.040 |
Why?
| | Celiac Disease | 1 | 2021 | 286 | 0.040 |
Why?
| | Glucosides | 1 | 2017 | 38 | 0.040 |
Why?
| | Immunologic Techniques | 2 | 1994 | 39 | 0.040 |
Why?
| | Sterols | 1 | 2017 | 18 | 0.030 |
Why?
| | Inositol Phosphates | 1 | 2017 | 23 | 0.030 |
Why?
| | Phosphorylation | 1 | 2002 | 1716 | 0.030 |
Why?
| | Botswana | 1 | 2017 | 8 | 0.030 |
Why?
| | International Cooperation | 1 | 2018 | 177 | 0.030 |
Why?
| | Cell Transformation, Neoplastic | 5 | 1977 | 319 | 0.030 |
Why?
| | Antigens, Bacterial | 1 | 2017 | 119 | 0.030 |
Why?
| | Health Surveys | 1 | 2019 | 495 | 0.030 |
Why?
| | Internationality | 1 | 2018 | 150 | 0.030 |
Why?
| | Patient Safety | 1 | 2020 | 291 | 0.030 |
Why?
| | Zimbabwe | 1 | 2017 | 53 | 0.030 |
Why?
| | Chemotaxis | 1 | 2017 | 130 | 0.030 |
Why?
| | Tanzania | 1 | 2017 | 49 | 0.030 |
Why?
| | Zambia | 1 | 2017 | 54 | 0.030 |
Why?
| | Bisoprolol | 1 | 1996 | 4 | 0.030 |
Why?
| | Plasma | 1 | 2018 | 206 | 0.030 |
Why?
| | Recovery of Function | 1 | 2021 | 645 | 0.030 |
Why?
| | Cerebrospinal Fluid | 2 | 1993 | 92 | 0.030 |
Why?
| | Acute Disease | 2 | 2011 | 980 | 0.030 |
Why?
| | Sinusitis | 1 | 1999 | 211 | 0.030 |
Why?
| | Biomarkers | 2 | 2018 | 3971 | 0.030 |
Why?
| | Immune Tolerance | 4 | 1998 | 356 | 0.030 |
Why?
| | Leukemia, Lymphoid | 2 | 1986 | 27 | 0.030 |
Why?
| | Propanolamines | 1 | 1996 | 97 | 0.030 |
Why?
| | False Negative Reactions | 1 | 1996 | 53 | 0.030 |
Why?
| | Public Health Surveillance | 1 | 2016 | 68 | 0.030 |
Why?
| | Cross-Sectional Studies | 4 | 2011 | 5085 | 0.030 |
Why?
| | False Positive Reactions | 1 | 1996 | 114 | 0.030 |
Why?
| | Amniocentesis | 2 | 1991 | 22 | 0.030 |
Why?
| | Predictive Value of Tests | 2 | 2010 | 1951 | 0.030 |
Why?
| | Inhibitor of Apoptosis Proteins | 1 | 2015 | 45 | 0.030 |
Why?
| | AIDS Dementia Complex | 1 | 2015 | 51 | 0.030 |
Why?
| | Depressive Disorder | 1 | 1998 | 367 | 0.030 |
Why?
| | Nevirapine | 1 | 2015 | 17 | 0.030 |
Why?
| | Half-Life | 2 | 1992 | 162 | 0.030 |
Why?
| | Analysis of Variance | 2 | 2011 | 1291 | 0.030 |
Why?
| | Nausea | 1 | 2015 | 111 | 0.030 |
Why?
| | Chi-Square Distribution | 2 | 2013 | 515 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2017 | 280 | 0.030 |
Why?
| | Vomiting | 1 | 2015 | 129 | 0.030 |
Why?
| | Area Under Curve | 1 | 2015 | 306 | 0.030 |
Why?
| | Bromodeoxyuridine | 2 | 2007 | 78 | 0.030 |
Why?
| | Fingolimod Hydrochloride | 1 | 2015 | 39 | 0.030 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2015 | 62 | 0.030 |
Why?
| | Breast Feeding | 1 | 2018 | 424 | 0.030 |
Why?
| | Neutropenia | 1 | 2015 | 137 | 0.030 |
Why?
| | Disease Susceptibility | 1 | 1996 | 334 | 0.030 |
Why?
| | Adrenergic beta-Antagonists | 1 | 1996 | 321 | 0.030 |
Why?
| | Belgium | 1 | 2014 | 12 | 0.030 |
Why?
| | Headache | 1 | 2015 | 151 | 0.030 |
Why?
| | Vaccines, Virus-Like Particle | 1 | 2014 | 3 | 0.030 |
Why?
| | Metabolic Diseases | 1 | 2015 | 104 | 0.030 |
Why?
| | HLA-A2 Antigen | 1 | 2014 | 48 | 0.030 |
Why?
| | Rubella | 1 | 1974 | 23 | 0.030 |
Why?
| | Culture Media | 2 | 1984 | 162 | 0.030 |
Why?
| | Tetanus Toxoid | 1 | 1994 | 37 | 0.030 |
Why?
| | Probability | 2 | 2005 | 304 | 0.030 |
Why?
| | Immunoblotting | 1 | 1994 | 306 | 0.030 |
Why?
| | Hemagglutinin Glycoproteins, Influenza Virus | 1 | 1994 | 23 | 0.030 |
Why?
| | Drugs, Investigational | 1 | 2014 | 32 | 0.030 |
Why?
| | Anemia | 1 | 2015 | 162 | 0.030 |
Why?
| | Seroepidemiologic Studies | 1 | 2014 | 157 | 0.030 |
Why?
| | Statistics, Nonparametric | 2 | 2004 | 422 | 0.030 |
Why?
| | Phenotype | 1 | 2002 | 3062 | 0.030 |
Why?
| | Mortality | 1 | 2015 | 308 | 0.030 |
Why?
| | Thrombocytopenia | 1 | 2015 | 189 | 0.030 |
Why?
| | Developed Countries | 1 | 2013 | 33 | 0.030 |
Why?
| | Haplorhini | 8 | 1974 | 51 | 0.030 |
Why?
| | Drug Tolerance | 1 | 1992 | 90 | 0.020 |
Why?
| | Arthritis, Rheumatoid | 1 | 2021 | 1098 | 0.020 |
Why?
| | Human papillomavirus 6 | 1 | 2011 | 3 | 0.020 |
Why?
| | Ureaplasma Infections | 1 | 1991 | 3 | 0.020 |
Why?
| | Skin | 2 | 1989 | 725 | 0.020 |
Why?
| | Mycoplasma Infections | 1 | 1991 | 15 | 0.020 |
Why?
| | Early Detection of Cancer | 1 | 2016 | 371 | 0.020 |
Why?
| | Safety | 1 | 1994 | 335 | 0.020 |
Why?
| | Genetics, Microbial | 3 | 1971 | 10 | 0.020 |
Why?
| | Metabolomics | 1 | 2017 | 652 | 0.020 |
Why?
| | Consensus | 1 | 2015 | 622 | 0.020 |
Why?
| | Genitalia, Female | 1 | 2012 | 38 | 0.020 |
Why?
| | gamma-Globulins | 1 | 1991 | 18 | 0.020 |
Why?
| | Epstein-Barr Virus Nuclear Antigens | 1 | 1991 | 10 | 0.020 |
Why?
| | Antibodies, Heterophile | 1 | 1991 | 14 | 0.020 |
Why?
| | Absenteeism | 1 | 2012 | 47 | 0.020 |
Why?
| | Inflammation | 2 | 2017 | 2748 | 0.020 |
Why?
| | Adenoviruses, Human | 1 | 1991 | 27 | 0.020 |
Why?
| | Hospitals, University | 1 | 1991 | 180 | 0.020 |
Why?
| | Adrenal Cortex Hormones | 1 | 2015 | 532 | 0.020 |
Why?
| | Matched-Pair Analysis | 1 | 2011 | 40 | 0.020 |
Why?
| | Bodily Secretions | 1 | 2010 | 1 | 0.020 |
Why?
| | Europe | 1 | 2012 | 363 | 0.020 |
Why?
| | North America | 1 | 2012 | 294 | 0.020 |
Why?
| | Diagnosis, Differential | 3 | 2009 | 1434 | 0.020 |
Why?
| | Paramyxoviridae Infections | 1 | 1990 | 12 | 0.020 |
Why?
| | Tritium | 7 | 1974 | 75 | 0.020 |
Why?
| | Chlamydia Infections | 1 | 1991 | 72 | 0.020 |
Why?
| | Schwann Cells | 1 | 1990 | 32 | 0.020 |
Why?
| | Bacterial Infections | 2 | 2001 | 234 | 0.020 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2015 | 753 | 0.020 |
Why?
| | DNA | 4 | 1988 | 1406 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2018 | 2378 | 0.020 |
Why?
| | Antigens | 2 | 1970 | 356 | 0.020 |
Why?
| | Rhinovirus | 1 | 1990 | 56 | 0.020 |
Why?
| | Antigens, Surface | 2 | 1987 | 152 | 0.020 |
Why?
| | Serotyping | 2 | 1988 | 28 | 0.020 |
Why?
| | Health Planning Guidelines | 1 | 2010 | 25 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2017 | 1686 | 0.020 |
Why?
| | Self Administration | 1 | 2010 | 122 | 0.020 |
Why?
| | Gestational Age | 2 | 1989 | 876 | 0.020 |
Why?
| | Hepatitis B Antibodies | 1 | 2009 | 11 | 0.020 |
Why?
| | beta-Globins | 1 | 2009 | 8 | 0.020 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2016 | 573 | 0.020 |
Why?
| | In Situ Hybridization | 2 | 2001 | 296 | 0.020 |
Why?
| | Contraceptive Devices, Male | 1 | 1989 | 1 | 0.020 |
Why?
| | Subacute Sclerosing Panencephalitis | 1 | 1989 | 5 | 0.020 |
Why?
| | Spermatocidal Agents | 1 | 1989 | 7 | 0.020 |
Why?
| | Ribonucleosides | 1 | 1989 | 6 | 0.020 |
Why?
| | Reference Values | 1 | 2011 | 796 | 0.020 |
Why?
| | Physical Examination | 1 | 2010 | 234 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 1993 | 1690 | 0.020 |
Why?
| | Thymidine | 4 | 1980 | 60 | 0.020 |
Why?
| | RNA, Antisense | 1 | 1988 | 16 | 0.020 |
Why?
| | Reference Standards | 1 | 2009 | 176 | 0.020 |
Why?
| | Nasal Mucosa | 1 | 2009 | 107 | 0.020 |
Why?
| | Astrocytes | 1 | 1990 | 197 | 0.020 |
Why?
| | Virus Cultivation | 4 | 1984 | 28 | 0.020 |
Why?
| | Reoviridae | 1 | 1988 | 37 | 0.020 |
Why?
| | Mammalian orthoreovirus 3 | 1 | 1988 | 37 | 0.020 |
Why?
| | Disease Progression | 1 | 2016 | 2628 | 0.020 |
Why?
| | Measles | 1 | 1989 | 44 | 0.020 |
Why?
| | Hepatitis | 1 | 1988 | 47 | 0.020 |
Why?
| | DNA, Recombinant | 1 | 1988 | 46 | 0.020 |
Why?
| | Cancer Vaccines | 1 | 2009 | 164 | 0.020 |
Why?
| | Reoviridae Infections | 1 | 1988 | 54 | 0.020 |
Why?
| | Health Services Needs and Demand | 1 | 2010 | 263 | 0.020 |
Why?
| | Fetus | 1 | 1992 | 782 | 0.020 |
Why?
| | Neoplasms, Experimental | 1 | 1969 | 171 | 0.020 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 1988 | 151 | 0.020 |
Why?
| | Cytopathogenic Effect, Viral | 2 | 1982 | 14 | 0.020 |
Why?
| | Body Fluids | 1 | 1987 | 63 | 0.020 |
Why?
| | Telomere | 1 | 2010 | 232 | 0.020 |
Why?
| | Australia | 1 | 2008 | 243 | 0.020 |
Why?
| | Noma | 1 | 1986 | 2 | 0.020 |
Why?
| | Heptavalent Pneumococcal Conjugate Vaccine | 1 | 2006 | 12 | 0.020 |
Why?
| | Biliary Atresia | 1 | 1988 | 161 | 0.020 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 1988 | 123 | 0.020 |
Why?
| | Valine | 1 | 2007 | 81 | 0.020 |
Why?
| | Open Reading Frames | 1 | 2007 | 114 | 0.020 |
Why?
| | Apoptosis | 1 | 2015 | 2489 | 0.020 |
Why?
| | Anti-Bacterial Agents | 2 | 1999 | 1708 | 0.020 |
Why?
| | Kidney | 9 | 1975 | 1383 | 0.020 |
Why?
| | Embryo, Mammalian | 3 | 1973 | 224 | 0.020 |
Why?
| | Mass Screening | 1 | 2014 | 1192 | 0.020 |
Why?
| | Interleukin-4 | 2 | 1998 | 212 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2007 | 284 | 0.020 |
Why?
| | Ketones | 1 | 1986 | 48 | 0.020 |
Why?
| | Biopsy | 1 | 1989 | 1089 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2006 | 306 | 0.020 |
Why?
| | Reagent Kits, Diagnostic | 1 | 1985 | 43 | 0.020 |
Why?
| | Residence Characteristics | 1 | 2008 | 332 | 0.020 |
Why?
| | Nectins | 1 | 2005 | 5 | 0.020 |
Why?
| | Lymphoproliferative Disorders | 1 | 1985 | 54 | 0.010 |
Why?
| | California | 1 | 2006 | 400 | 0.010 |
Why?
| | Toll-Like Receptor 2 | 1 | 2005 | 113 | 0.010 |
Why?
| | Factor Analysis, Statistical | 1 | 2006 | 284 | 0.010 |
Why?
| | Streptococcus pneumoniae | 1 | 2006 | 161 | 0.010 |
Why?
| | Carbon Isotopes | 5 | 1973 | 127 | 0.010 |
Why?
| | Intensive Care Units, Neonatal | 1 | 1988 | 228 | 0.010 |
Why?
| | Chromosomes, Human | 1 | 1984 | 41 | 0.010 |
Why?
| | Toll-Like Receptors | 1 | 2005 | 179 | 0.010 |
Why?
| | Cytotoxicity, Immunologic | 1 | 1985 | 220 | 0.010 |
Why?
| | Hexuronic Acids | 1 | 1984 | 23 | 0.010 |
Why?
| | Glucuronic Acid | 1 | 1984 | 25 | 0.010 |
Why?
| | Alginates | 1 | 1984 | 46 | 0.010 |
Why?
| | Freezing | 1 | 1984 | 87 | 0.010 |
Why?
| | Filtration | 1 | 1984 | 67 | 0.010 |
Why?
| | Polyethylene Glycols | 1 | 1989 | 612 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2007 | 778 | 0.010 |
Why?
| | Culture Techniques | 4 | 1973 | 81 | 0.010 |
Why?
| | Bone Marrow Cells | 1 | 1984 | 302 | 0.010 |
Why?
| | RNA, Small Interfering | 1 | 2005 | 590 | 0.010 |
Why?
| | Fetal Blood | 1 | 1985 | 318 | 0.010 |
Why?
| | Transcription, Genetic | 4 | 1977 | 1416 | 0.010 |
Why?
| | Socioeconomic Factors | 1 | 2007 | 1214 | 0.010 |
Why?
| | Stomatitis, Herpetic | 1 | 1982 | 5 | 0.010 |
Why?
| | Phosphonoacetic Acid | 1 | 1982 | 10 | 0.010 |
Why?
| | Up-Regulation | 1 | 2005 | 836 | 0.010 |
Why?
| | Prognosis | 1 | 2010 | 3773 | 0.010 |
Why?
| | Agammaglobulinemia | 1 | 1982 | 33 | 0.010 |
Why?
| | NF-kappa B | 1 | 2005 | 666 | 0.010 |
Why?
| | Interleukin-6 | 1 | 2005 | 724 | 0.010 |
Why?
| | Ulnar Nerve | 1 | 2001 | 16 | 0.010 |
Why?
| | Brain | 1 | 1993 | 2677 | 0.010 |
Why?
| | Temperature | 1 | 1984 | 635 | 0.010 |
Why?
| | Administration, Oral | 2 | 1997 | 787 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 1991 | 4077 | 0.010 |
Why?
| | Cell Survival | 1 | 1984 | 1086 | 0.010 |
Why?
| | Phytohemagglutinins | 1 | 1980 | 29 | 0.010 |
Why?
| | Serum Albumin | 1 | 2001 | 149 | 0.010 |
Why?
| | Ambulatory Care | 1 | 2004 | 509 | 0.010 |
Why?
| | Neuroglia | 1 | 2001 | 167 | 0.010 |
Why?
| | Cell Communication | 1 | 1982 | 301 | 0.010 |
Why?
| | Phagocytosis | 1 | 1982 | 362 | 0.010 |
Why?
| | Air Microbiology | 1 | 1980 | 40 | 0.010 |
Why?
| | Leukocytes | 1 | 1981 | 306 | 0.010 |
Why?
| | Nasal Decongestants | 1 | 1999 | 8 | 0.010 |
Why?
| | Immunity, Maternally-Acquired | 1 | 1979 | 19 | 0.010 |
Why?
| | Otorhinolaryngologic Surgical Procedures | 1 | 1999 | 37 | 0.010 |
Why?
| | Immunoglobulins | 1 | 1979 | 162 | 0.010 |
Why?
| | Mitogens | 1 | 1978 | 61 | 0.010 |
Why?
| | Steroids | 1 | 1999 | 158 | 0.010 |
Why?
| | Lectins | 1 | 1978 | 48 | 0.010 |
Why?
| | Cross Infection | 1 | 1980 | 219 | 0.010 |
Why?
| | Rabbits | 1 | 1979 | 778 | 0.010 |
Why?
| | Th2 Cells | 1 | 1998 | 171 | 0.010 |
Why?
| | Amanitins | 1 | 1977 | 4 | 0.010 |
Why?
| | Bronchopulmonary Dysplasia | 2 | 1993 | 378 | 0.010 |
Why?
| | Centrifugation, Density Gradient | 3 | 1971 | 39 | 0.010 |
Why?
| | Antigen-Antibody Complex | 1 | 1997 | 86 | 0.010 |
Why?
| | Interleukin-10 | 1 | 1998 | 304 | 0.010 |
Why?
| | Erythrocytes | 1 | 1982 | 673 | 0.010 |
Why?
| | Combined Modality Therapy | 1 | 1999 | 1201 | 0.010 |
Why?
| | Adenoviridae Infections | 1 | 1975 | 17 | 0.010 |
Why?
| | Patient Selection | 1 | 1999 | 660 | 0.010 |
Why?
| | Heart Defects, Congenital | 2 | 1993 | 796 | 0.010 |
Why?
| | Indicator Dilution Techniques | 1 | 1994 | 11 | 0.010 |
Why?
| | Uridine | 2 | 1973 | 29 | 0.010 |
Why?
| | Evidence-Based Medicine | 1 | 1999 | 716 | 0.010 |
Why?
| | Centrifugation, Zonal | 2 | 1971 | 2 | 0.010 |
Why?
| | Abortion, Therapeutic | 1 | 1974 | 3 | 0.010 |
Why?
| | Rubella virus | 1 | 1974 | 6 | 0.010 |
Why?
| | Cesium | 2 | 1971 | 20 | 0.010 |
Why?
| | Molecular Biology | 2 | 1971 | 57 | 0.010 |
Why?
| | Sucrose | 2 | 1971 | 103 | 0.010 |
Why?
| | Microscopy, Electron | 2 | 1990 | 425 | 0.010 |
Why?
| | Chlorides | 2 | 1971 | 139 | 0.010 |
Why?
| | Complement Fixation Tests | 2 | 1984 | 6 | 0.010 |
Why?
| | Pulmonary Fibrosis | 1 | 1975 | 385 | 0.010 |
Why?
| | Hemagglutination Tests | 1 | 1991 | 7 | 0.010 |
Why?
| | Genes | 1 | 1971 | 225 | 0.010 |
Why?
| | Population Surveillance | 1 | 1993 | 439 | 0.010 |
Why?
| | Stress, Psychological | 1 | 1998 | 1070 | 0.010 |
Why?
| | Nonoxynol | 1 | 1989 | 4 | 0.000 |
Why?
| | Latex | 1 | 1989 | 9 | 0.000 |
Why?
| | Kidney Transplantation | 1 | 1975 | 670 | 0.000 |
Why?
| | Ribonucleases | 1 | 1987 | 54 | 0.000 |
Why?
| | Suspensions | 1 | 1987 | 36 | 0.000 |
Why?
| | Chloroquine | 1 | 1987 | 51 | 0.000 |
Why?
| | Deltaretrovirus | 1 | 1986 | 12 | 0.000 |
Why?
| | Binding, Competitive | 1 | 1985 | 206 | 0.000 |
Why?
| | Leukocyte Count | 1 | 1985 | 326 | 0.000 |
Why?
| | Mitosis | 1 | 1985 | 180 | 0.000 |
Why?
| | Histocompatibility Antigens Class II | 1 | 1985 | 363 | 0.000 |
Why?
| | Serologic Tests | 1 | 1983 | 52 | 0.000 |
Why?
| | Histocompatibility Antigens | 2 | 1974 | 107 | 0.000 |
Why?
| | Infusions, Parenteral | 1 | 1982 | 38 | 0.000 |
Why?
| | Leukemia | 1 | 1983 | 230 | 0.000 |
Why?
| | Hospital Bed Capacity, 300 to 499 | 1 | 1980 | 4 | 0.000 |
Why?
| | Air Movements | 1 | 1980 | 10 | 0.000 |
Why?
| | Hospital Units | 1 | 1980 | 24 | 0.000 |
Why?
| | Liver | 1 | 1988 | 1839 | 0.000 |
Why?
| | Boston | 1 | 1980 | 89 | 0.000 |
Why?
| | Communicable Disease Control | 1 | 1980 | 75 | 0.000 |
Why?
| | Methods | 1 | 1978 | 64 | 0.000 |
Why?
| | p-Fluorophenylalanine | 1 | 1976 | 2 | 0.000 |
Why?
| | Cycloheximide | 1 | 1976 | 55 | 0.000 |
Why?
| | Hospitals, Pediatric | 1 | 1980 | 517 | 0.000 |
Why?
| | Inclusion Bodies, Viral | 1 | 1975 | 2 | 0.000 |
Why?
| | Cytoplasm | 1 | 1976 | 269 | 0.000 |
Why?
| | Cadaver | 1 | 1975 | 308 | 0.000 |
Why?
| | Transplantation, Homologous | 1 | 1975 | 402 | 0.000 |
Why?
| | Genetic Code | 1 | 1971 | 20 | 0.000 |
Why?
| | Postoperative Complications | 1 | 1983 | 2481 | 0.000 |
Why?
| | Nucleic Acid Denaturation | 1 | 1971 | 32 | 0.000 |
Why?
| | Chymotrypsin | 1 | 1971 | 19 | 0.000 |
Why?
| | Platinum | 1 | 1971 | 44 | 0.000 |
Why?
| | Molecular Weight | 1 | 1971 | 330 | 0.000 |
Why?
| | DNA Replication | 1 | 1971 | 225 | 0.000 |
Why?
| | Carbon | 1 | 1971 | 206 | 0.000 |
Why?
| | Hot Temperature | 1 | 1971 | 369 | 0.000 |
Why?
| | Lung | 1 | 1975 | 3940 | 0.000 |
Why?
|
|
Levin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|